1. Atherosclerosis. 2019 Oct;289:162-172. doi: 
10.1016/j.atherosclerosis.2019.08.020. Epub 2019 Aug 30.

The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9.

Sánchez-Hernández RM(1), Di Taranto MD(2), Benito-Vicente A(3), Uribe KB(3), 
Lamiquiz-Moneo I(4), Larrea-Sebal A(3), Jebari S(3), Galicia-Garcia U(5), Nóvoa 
FJ(1), Boronat M(1), Wägner AM(1), Civeira F(4), Martín C(6), Fortunato G(7).

Author information:
(1)Sección de Endocrinología y Nutrición, Complejo Hospitalario Universitario 
Insular Materno Infantil de Gran Canaria, Instituto Universitario de 
Investigaciones Biomédicas y Sanitarias (IUIBS) de la Universidad de Las Palmas 
de Gran Canaria, Las Palmas de Gran Canaria, Spain.
(2)Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli 
Studi di Napoli Federico II, Napoli and CEINGE S.C.a r.l, Biotecnologie 
Avanzate, Napoli, Italy.
(3)Instituto Biofisika (UPV/EHU, CSIC) and Departamento de Bioquímica, 
Universidad del País Vasco, Apdo. 644, 48080, Bilbao, Spain.
(4)Hospital Universitario Miguel Servet. IIS Aragon. CIBERCV. Universidad de 
Zaragoza, Zaragoza, Spain.
(5)Instituto Biofisika (UPV/EHU, CSIC), Barrio Sarriena s/n, 48940, Leioa, 
Bizkaia, Spain.
(6)Instituto Biofisika (UPV/EHU, CSIC) and Departamento de Bioquímica, 
Universidad del País Vasco, Apdo. 644, 48080, Bilbao, Spain. Electronic address: 
cesar.martin@ehu.eus.
(7)Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli 
Studi di Napoli Federico II, Napoli and CEINGE S.C.a r.l, Biotecnologie 
Avanzate, Napoli, Italy. Electronic address: fortunat@unina.it.

BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is a monogenic disease 
characterized by high levels of low-density lipoprotein cholesterol and 
premature atherosclerotic cardiovascular disease. FH is caused by loss of 
function mutations in genes encoding LDL receptor (LDLR), and Apolipoprotein B 
(APOB) or gain of function (GOF) mutations in proprotein convertase 
subtilisin/kexin type 9 (PCSK9). In this study, we identified a novel variant in 
PCSK9, p.(Arg499His), located in the C-terminal domain, in two unrelated FH 
patients from Spain and Italy.
METHODS: We studied familial segregation and determined variant activity in 
vitro.
RESULTS: We determined PCSK9 expression, secretion and activity of the variant 
in transfected HEK293 cells; extracellular activity of the recombinant 
p.(Arg499His) PCSK9 variant in HEK 293 and HepG2 cells; PCSK9 affinity to the 
LDL receptor at neutral and acidic pH; the mechanism of action of the 
p.(Arg499His) PCSK9 variant by co-transfection with a soluble construct of the 
LDL receptor and by determining total PCSK9 intracellular accumulation when 
endosomal acidification is impaired and when an excess of soluble LDLr is 
present in the culture medium. Our results show high LDL-C concentrations and FH 
phenotype in p.(Arg499His) carriers. In vitro functional characterization shows 
that p.(Arg499His) PCSK9 variant causes a reduction in LDLr expression and LDL 
uptake. An intracellular activity for this variant is also shown when blocking 
the activity of secreted PCSK9 and by inhibiting endosomal acidification.
CONCLUSIONS: We demonstrated that p.(Arg499His) PCSK9 variant causes a direct 
intracellular degradation of LDLr therefore causing FH by reducing LDLr 
availability.

Copyright © 2019 Elsevier B.V. All rights reserved.

DOI: 10.1016/j.atherosclerosis.2019.08.020
PMID: 31518966 [Indexed for MEDLINE]